Clinical trials are conducted in sequential phases, each designed to answer different questions about a new treatment. Understanding these phases helps you evaluate where a treatment is in its development and what participating in a given phase involves.
Phase 1: Safety and Dosage
Purpose: Determine the safe dosage range and identify side effects.
Participants: Typically 20–80 people. In oncology, Phase 1 participants are usually patients with advanced cancer who have exhausted standard options. In other fields, healthy volunteers may participate.
Design: Often uses a dose-escalation approach — small groups receive increasing doses to find the maximum tolerated dose. Participants are monitored very closely.
Duration: Several months to a year.
Success rate: About 70% of Phase 1 treatments move to Phase 2.
What it means for you: Phase 1 trials involve the most uncertainty because the treatment has not been extensively tested in humans. Monitoring is very frequent, which means more visits but also closer medical attention.
Phase 2: Effectiveness
Purpose: Determine whether the treatment works for the intended condition and further evaluate safety.
Participants: Typically 100–300 people with the specific condition being studied.
Design: May be single-arm (everyone receives the treatment) or randomised (some receive the treatment, others receive standard care or placebo). Researchers measure specific outcomes to assess whether the treatment has a meaningful effect.
Duration: Several months to two years.
Success rate: About 33% of Phase 2 treatments move to Phase 3. This is the phase where many treatments fail because they do not show enough benefit.
What it means for you: Phase 2 trials have preliminary safety data from Phase 1, so the risk profile is better understood. You are more likely to receive the study treatment (especially in single-arm designs).
Phase 3: Confirmation
Purpose: Confirm effectiveness in a large population, monitor side effects, compare against existing treatments, and collect data for regulatory approval.
Participants: Typically 1,000–3,000+ people across multiple sites and often multiple countries.
Design: Usually randomised and often double-blinded (neither participants nor researchers know who receives which treatment). The control group typically receives the current standard of care, not a placebo alone.
Duration: One to four years.
Success rate: About 50–60% of Phase 3 treatments are approved by regulatory agencies.
What it means for you: Phase 3 trials have the most data behind them from earlier phases. The treatment has already shown promise. These trials are the closest step to an approved therapy.
Phase 4: Post-Approval Monitoring
Purpose: Gather long-term safety and effectiveness data after a treatment has been approved and is available to the public.
Participants: Thousands to tens of thousands of people using the approved treatment.
Design: Often observational — tracking outcomes in patients who are prescribed the treatment as part of routine care. Some Phase 4 studies test the treatment in new populations or for new conditions.
Duration: Ongoing, can last many years.
What it means for you: Phase 4 involves an already-approved treatment, so the risk profile is well-established. These studies help identify rare side effects that may not have appeared in earlier phases.
Frequently Asked Questions
Which phase is safest for participants?
Phase 4 and Phase 3 trials generally have the most safety data available, since the treatment has been tested in prior phases. Phase 1 trials carry the most uncertainty. However, all phases have safety monitoring in place, and the level of oversight is highest in Phase 1.
Can a treatment skip phases?
Rarely. In urgent situations (such as a pandemic), regulators may allow accelerated or combined phase designs (e.g., Phase 1/2 or Phase 2/3), but the core safety and efficacy questions must still be answered. No phase is truly skipped.
What is a Phase 1/2 or Phase 2/3 trial?
These are combined-phase trials that test safety and efficacy simultaneously. They are designed to speed up the development timeline while still collecting the necessary data. You may see these described as "seamless" or "adaptive" designs.
Does the phase tell me how effective the treatment is?
Not directly. Phase 1 trials are not designed to measure effectiveness. Phase 2 trials provide preliminary effectiveness data. Phase 3 trials provide the strongest evidence of effectiveness because they use large groups and controlled comparisons.